Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial

NCT07854730 | Not Yet Recruiting

• 1 other identifier: IRB # 14/5/2025-2026
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.

Conditions

Ventilator Associated Bacterial Pneumonia (VABP); Critical Illness

Outcome Measures

Primary Outcomes (4)

• PaCO2

  partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide

  Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

• PaO2

  partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test.

  Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

• SaO2

  the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99%

  Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

• PaO2/FiO2 (P/F)

  a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS).

  Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Secondary Outcomes (1)

• Pulmonary compliance

  Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Study Arms (2)

ventilator hyperinflation from lateral decubitus position

EXPERIMENTAL

This group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy

Device: Ventilator hyperinflation

Manual hyperinflation for Lateral decubitus position

EXPERIMENTAL

This group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy

Device: Manual hyperinflation

Interventions

Ventilator hyperinflation DEVICE

a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic

ventilator hyperinflation from lateral decubitus position

Manual hyperinflation DEVICE

a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas

Manual hyperinflation for Lateral decubitus position

Eligibility Criteria

• Age: 40 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Mechanically ventilated patients ≥ 48 hours
• Diagnosed with VAP (clinical + chest X-ray)
• Age: 40-60 years
• Hemodynamically stable
• Unilateral lung involvement

You may not qualify if:

• Bilateral lung disease
• Unstable cardiovascular conditions
• Contraindications to positioning
• Re-intubation cases
• Presence of pneumothorax or air leak

Sponsors & Collaborators

• Al-Zaytoonah University of Jordan: lead

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor doctor

Study Record Dates

• First Submitted: September 27, 2026
• First Posted: October 2, 2026
• Study Start (Estimated): October 5, 2026
• Primary Completion (Estimated): November 15, 2026
• Study Completion (Estimated): November 15, 2026
• Last Updated: October 2, 2026

Record last verified: 2026-09